Do you want to read an article? Please log in or register.
Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A
doi: 10.1093/ibd/izz144.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC
Clin Gastroenterol Hepatol.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ
doi: 10.1016/j.cgh.2019.11.059.
Inflammatory Bowel Disease
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
Eur J Gastroenterol Hepatol.
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D
doi: 10.1097/MEG.
Inflammatory Bowel Disease
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials
Clin Gastroenterol Hepatol.
Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V
doi: 10.1016/j.cgh.2019.05.019.
Inflammatory Bowel Disease
Cannabis for the treatment of ulcerative colitis
Cochrane Database Syst Rev.
Kafil TS, Nguyen TM, MacDonald JK, Chande N
doi: 10.1002/14651858.
Inflammatory Bowel Disease
Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data
J Crohns Colitis.
Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH, Swiss IBD Cohort study group.
doi: 10.1093/ecco-jcc/jjz169.
Inflammatory Bowel Disease
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
United European Gastroenterol J.
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F
doi: 10.1177/2050640619895361.
Inflammatory Bowel Disease
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study
United European Gastroenterol J
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Girolamo MD, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A, on behalf on the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
doi: 10.1177/2050640620974308